Apyx Medical Corporation
APYXNASDAQHealthcare● Active
$4.77
+$0.30(+6.71%)
Market Cap$199738746
P/E Ratio—
52W High$4.99
52W Low$1.59
Apyx Medical Corporation (APYX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
APYX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.05
Est. -$0.11 · +54.5%
Revenue
$0.01B
Est. $0.01B · +18.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
APYX reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.09 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.11 | -$0.05 | +54.5% | $0.01B | $0.01B | +18.7% |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$0.06 | -$0.03 | +50.0% | $0.02B | $0.02B | +3.4% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.06 | -$0.05 | +16.7% | $0.01B | $0.02B | -28.9% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.09 | -$0.09 | +3.6% | $0.01B | $0.01B | -2.8% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.12 | -$0.10 | +16.7% | $0.01B | $0.01B | +1.0% |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.13 | -$0.12 | +7.7% | $0.01B | $0.01B | +44.0% |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$0.15 | -$0.14 | +6.7% | $0.01B | $0.01B | -11.8% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.11
EPS Surpr.
+54.5%
Revenue
$0.01B
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$0.03
EPS Est.
-$0.06
EPS Surpr.
+50.0%
Revenue
$0.02B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.09
EPS Surpr.
+3.6%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.12
EPS Surpr.
+16.7%
Revenue
$0.01B
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.13
EPS Surpr.
+7.7%
Revenue
$0.01B
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.15
EPS Surpr.
+6.7%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2028 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2028 | $-0.05 | $-0.05 | $-0.04 | 1 |
| Q4 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2027 | $-0.08 | $-0.08 | $-0.07 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +54.5% | $2.92 | $3.56 | +21.92% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +50.0% | $3.43 | $3.45 | +0.58% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +16.7% | $3.14 | $3.35 | +6.69% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +3.6% | $2.04 | $1.96 | -3.92% |
| ▲ Q2 FY2025 | May 8, 2025 | +16.7% | $1.25 | $1.18 | -5.60% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +7.7% | $1.07 | $1.04 | -2.80% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +6.7% | $1.22 | $1.52 | +24.59% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -5.6% | $1.01 | $1.02 | +0.99% |
Q2 FY2026+21.92%
Report Date
May 7, 2026
EPS Beat/Miss
+54.5%
Price Before
$2.92
Price After
$3.56
Q1 FY2026+0.58%
Report Date
Mar 10, 2026
EPS Beat/Miss
+50.0%
Price Before
$3.43
Price After
$3.45
Q4 FY2025+6.69%
Report Date
Nov 6, 2025
EPS Beat/Miss
+16.7%
Price Before
$3.14
Price After
$3.35
Q3 FY2025-3.92%
Report Date
Aug 7, 2025
EPS Beat/Miss
+3.6%
Price Before
$2.04
Price After
$1.96
Q2 FY2025-5.60%
Report Date
May 8, 2025
EPS Beat/Miss
+16.7%
Price Before
$1.25
Price After
$1.18
Q1 FY2025-2.80%
Report Date
Mar 13, 2025
EPS Beat/Miss
+7.7%
Price Before
$1.07
Price After
$1.04
Q4 FY2024+24.59%
Report Date
Nov 8, 2024
EPS Beat/Miss
+6.7%
Price Before
$1.22
Price After
$1.52
Q3 FY2024+0.99%
Report Date
Aug 8, 2024
EPS Beat/Miss
-5.6%
Price Before
$1.01
Price After
$1.02
Avg Beat Reaction+5.92%
Avg Miss Reaction+0.99%
Beat Rate7 / 8 quarters
Largest Move+24.59% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: APYX ends December
Apyx Medical Corporation (APYX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.05 — beating the analyst consensus of $-0.11 by +54.5%. APYX has beaten EPS estimates for 7 consecutive quarters. The next APYX earnings date is expected around September 1, 2026.
Each quarter, investors track APYX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APYX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
APYX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
APYX earnings · 5 questionsApyx Medical Corporation's next earnings report is expected around September 1, 2026. APYX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APYX historically reports after market close (AMC).
APYX earnings datewhen is APYX earningsAPYX next earnings datewhen does APYX report earningsAPYX earnings calendar
▸ Source: FMP · Apyx Medical Corporation SEC filings · US GAAP · Apyx Medical Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026